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Ischemia–reperfusion (IR) injury to the kidney occurs in a range of clinically important scenarios
including hypotension, sepsis and in surgical procedures such as cardiac bypass surgery and kidney
transplantation, leading to acute kidney injury (AKI). Mitochondrial oxidative damage is a signiﬁcant
contributor to the early phases of IR injury and may initiate a damaging inﬂammatory response. Here we
assessed whether the mitochondria targeted antioxidant MitoQ could decrease oxidative damage during
IR injury and thereby protect kidney function. To do this we exposed kidneys in mice to in vivo ischemia
by bilaterally occluding the renal vessels followed by reperfusion for up to 24 h. This caused renal
dysfunction, measured by decreased creatinine clearance, and increased markers of oxidative damage.
Administering MitoQ to the mice intravenously 15 min prior to ischemia protected the kidney from
damage and dysfunction. These data indicate that mitochondrial oxidative damage contributes to kidney
IR injury and that mitochondria targeted antioxidants such as MitoQ are potential therapies for renal
dysfunction due to IR injury.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
The kidney is vulnerable to ischemia–reperfusion (IR) injury
during a number of clinically important scenarios, including
hypotension, sepsis, surgical procedures such as partial
nephrectomy and cardiac bypass surgery, as well as during kidney
transplantation [1,2]. The clinical consequences of renal IR injury –
or ischemic acute kidney injury (AKI) as the clinical syndrome is
called – depend on the severity of the injury, and range from
minor changes in renal function to a requirement for dialysis or
transplantation [3]. Ischemic AKI is a major cause of morbidity and
mortality [4], for example it can predispose to chronic kidney
disease and contributes to delayed graft function and rejection
following transplantation [5]. Currently there is no effective
pharmacological strategy to address the underlying pathophy-
siology of ischemic AKI.
As ischemic AKI often occurs in high-risk patient populations as
a result of predictable interventions such as cardiac bypass surgery
or following kidney transplantation, pre-treatments that protect
the kidney from IR injury are feasible. While protective agents
such as N-acetyl cysteine have shown some efﬁcacy against AKIB.V. This is an open access article
urphy).caused by radiological contrast agents [6], progress towards a
general strategy to decrease ischemic AKI has been frustratingly
slow. To address this unmet clinical need we focused on phar-
macological strategies aimed at protecting mitochondria, as
damage to these organelles is central to IR injury [7]. During renal
ischemia, oxygen deprivation depletes intracellular ATP, inacti-
vates oxidative phosphorylation and leads to a compensatory
switch to anaerobic metabolism [8]. Re-introduction of oxygen at
reperfusion dramatically increases the generation of the damaging
reactive oxygen species superoxide and hydrogen peroxide from
mitochondria [9–11] damaging cellular lipids, proteins and DNA
[9,12]. This disrupts mitochondrial ATP supply and in conjunction
with calcium uptake can induce the mitochondrial permeability
transition pore and thus cell death [13,14]. In addition, mito-
chondrial damage can activate inﬂammasome formation, aug-
menting the innate inﬂammatory response to tissue damage in the
hours following the initial insult [15–18]. Therefore mitochondrial
oxidative damage is a major factor in kidney IR injury.
A pharmacological method to decrease mitochondrial oxidative
damage is thus an appealing prospect for kidney IR injury [19].
Conventional antioxidants have not been effective clinically, in
large part because they are not taken up by the mitochondria
in vivo [20,21]. To overcome this limitation we developed mito-
chondria targeted antioxidants, the prototype of which is MitoQ
[22]. This molecule comprises a lipophilic triphenylphosphoniumunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Accumulation of MitoQ within kidney mitochondria driven by the mem-
brane potential. MitoQ accumulates within the cell driven by the plasma mem-
brane potential (ΔΨp), then further accumulates within mitochondria driven by
mitochondrial membrane potential (ΔΨm). In the mitochondrial matrix, MitoQ is
reduced to the active antioxidant form, ubiquinol, by the respiratory chain pre-
venting oxidative damage such as lipid peroxidation. Antioxidant activity generates
the ubiquinone form, which is then recycled back to ubiquinol by the respiratory
chain.
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Fig. 2. Renal ischemia–reperfusion (IR) injury in a mouse model. (A) 45 min
bilateral renal ischemia followed by reperfusion resulted in a signiﬁcant increase in
creatinine at 24 h compared to sham operated controls (laparotomy only) and
30 min ischemia (one-way ANOVA, p¼o0.0001, with Bonferroni's post-testing
between groups where ***po0.001). (B) Intravenous administration of MitoQ
15 min prior to the onset of 45 min bilateral renal ischemia, signiﬁcantly protected
against kidney injury, as demonstrated by a lower creatinine at 24 h. Administra-
tion of decylTPP (dTPP) without the ubiquinone antioxidant moiety did not protect
against IR injury. One-way ANOVA; p¼o0.0001, with Bonferroni's post-testing
between groups where *po0.05, ***po0.001. n¼4–5/group. Data are
means7SEM.
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an antioxidant ubiquinone moiety [23]. The TPP lipophilic cation
passes rapidly through biological membranes and its positive
charge drives the extensive accumulation of these molecules into
mitochondria, due to the large mitochondrial membrane potential
[22]. The ubiquinone moiety is activated and recycled by complex
II within mitochondria and acts as a chain breaking antioxidant to
prevent oxidative damage [20,23,24]. This combination of exten-
sive uptake into mitochondria [23], recycling of the antioxidant
moiety [25] and its location on the matrix facing surface of the
mitochondrial inner membrane [26] makes MitoQ many thousand
fold more potent at preventing oxidative damage than untargeted
antioxidants [23] (Fig. 1). MitoQ has been used extensively in
animal models of human pathologies [22] where it has been
shown to be effective following oral, intravenous or intraper-
itoneal delivery [22]. In addition, MitoQ has been used in two
Phase II trials in humans and been shown to be safe and well
tolerated long term [27] and effective at preventing liver inﬂam-
matory damage in a small study of hepatitis C virus-patients [28].
The use of MitoQ for AKI is supported by the fact that MitoQ is
rapidly cleared from the plasma following intravenous adminis-
tration and accumulates within the kidney [29,30]. Furthermore,
MitoQ decreases IR injury in other organs [15,31,32] and protects
the kidney against damage during cold storage [33] and from
diabetic nephropathy [34]. Together these ﬁndings suggest that
MitoQ may be an effective therapy for the acute kidney IR injury.
Here we have determined if the mitochondrial damage and kidney
dysfunction caused by IR injury could be decreased by MitoQ. To
do this we used a mouse model of bilateral renal ischemia, fol-
lowed by up to 24 h reperfusion. We found that IV administration
of MitoQ 15 min prior to ischemia was protective against kidney IR
injury.Materials and methods
In vivo mouse model of renal ischemia–reperfusion injury
Male C57BL/6 mice (25710 g) from Charles River Laboratories
were maintained in speciﬁc pathogen-free facilities, with ad lib
food and water. All animal studies were approved by the UK Home
Ofﬁce under the Animals (Scientiﬁc Procedures) Act 1986. Animals
were allocated to one of four treatment or control groups and
exposed to 45 min renal ischemia, or sham operation, 7MitoQ.
Kidneys from healthy animals not subjected to anesthesia or sur-
gery were taken as a baseline control. Under isoﬂuorane general
anesthesia, animals underwent laparotomy and exposure of the
renal hilum bilaterally. MitoQ (4 mg/kg; added as MitoQ adsorbed
to β-cyclodextran (MS010)) in 100 mL 0.9% saline was injected into
the tail vein 15 min before the onset of ischemia. The dose was
based on reported safety and efﬁcacy data [22]. DecylTPP, which is
similar to MitoQ but without the ubiquinone moiety (Fig. 1), was
used as a control. Vascular clips (8 mm, interFocus Fine Science
Tools, Cambridge, UK) were placed over both renal hila to induce
bilateral renal ischemia. At the end of ischemia the clips were
removed and kidney reperfusion noted as return of blush color
and visualization of ﬂow from the renal vein under microscopy.
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Fig. 3. Oxidative damage to proteins and mtDNA following renal ischemia and 24 h
reperfusion. (A) Protein carbonyl content in the kidney compared between sham
operated groups, IR only and MitoQþ IR groups (one-way ANOVA; p¼0.0046).
Bonferroni's post-testing demonstrated a signiﬁcant difference between the sham
surgery and IR groups at the level of po0.05, and between the IR and MitoQþ IR
groups at the level of po0.01. (B) mtDNA damage was measured using a quanti-
tative PCR technique. The sham-operated control was normalized to one and
relative ampliﬁcation of mtDNA in the IR and MitoQ groups compared to this. There
was a signiﬁcant difference in mtDNA ampliﬁcation between groups 24 h post IR
injury (one-way ANOVA; p¼o0.0001), suggesting signiﬁcant damage to mtDNA
had occurred. Bonferroni's post-testing demonstrated a signiﬁcant difference
between the sham surgery and IR groups at the level of po0.001, and between the
IR and MitoQþ IR groups at the level of po0.01. n¼4/group. *po0.05, **po0.01,
***po0.001. Data are means7SEM.
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ischemia followed by reperfusion for 60 min under anesthesia, or
for 24 h; the 24 h reperfusion groups were recovered following
reperfusion and the abdomen closed with 5.0 Monocryl suture
(Ethicon, United States). At the end of reperfusion, all animals
were euthanized by cervical dislocation under anesthesia. A blood
sample was collected using a heparinized syringe, centrifuged
(4000g for 10 min at 4 °C) and plasma was analyzed for creatinine
using an automated biochemical analyzer (Siemens Dimension
RxL Analyser, Siemens AG, Healthcare Division, Germany) at the
Core Biochemical Analysis Laboratory, Addenbrooke's Hospital,
Cambridge. Kidney tissue was ﬂash frozen in liquid nitrogen and
stored at  80 °C for later analysis.
Measurement of mitochondrial oxidative damage
To assess damage to mtDNA, total DNA was isolated from fro-
zen kidney tissue (20 mg wet weight) using the Qiagen DNeasy
Tissue Kit (Qiagen, UK), quantiﬁed using the PicoGreen dsDNA
Assay Kit (Invitrogen) diluted to 3 ng/mL in TE buffer (10 mM Tris,
1 mM EDTA, pH 7.5 (HCl)) and stored at 4 °C. Damage to mtDNA
was then assessed using a quantitative PCR method [35,36]. In this
method damage to DNA blocks progression of the polymeraseduring PCR, reducing ampliﬁcation for a long target (10 kb)
sequence relative to a short target (200 bp) that is used to
control for mtDNA copy number. Each PCR reaction was in a total
volume of 50 mL, comprising 15 ng DNA template, 35 mL PCR
Mastermix (100 ng/mL BSA, 200 mM NTPs, 20 pmol forward primer,
20 pmol reverse primer, 0.9 mM Mg(OAc)2, 12.55 mL H2O) and 1 U
rTth DNA polymerase XL (GeneAmp, Applied Biosystems). The
primer sequences were: forward primer (long and short) 5′-
GCCAGCCTGACCCATAGCCATAAT, reverse (short) primer 5′-
GCCGGCTGCGTATTCTACGTTA, reverse (long) primer 5′-GAGA-
GATTTTATGGGTGTAATGCGG. The PCR parameters for the short
mitochondrial target were 18 cycles of 30 s at 94 °C, 45 s at 64 °C,
45 s at 72 °C, 10 min at 72 °C. Parameters for the long mitochon-
drial target were 1 min at 94 °C followed by 16 cycles of 15 s at
94 °C and 12 min at 64 °C, followed by 10 min at 72 °C [37]. Each
sample was ampliﬁed in duplicate, along with a 50% dilution and a
non-template control. The number of PCR cycles was selected so
that the reaction remained within the linear phase, deﬁned as
ampliﬁcation of 5 ng DNA producing 40–60% of that of ampliﬁ-
cation of 10 ng untreated control [37]. Reactions that meet this
criterion were then quantiﬁed by the Picogreen assay, corrected
for the non-template control. Ampliﬁcation of the long PCR target
was then normalized to that of the short target and compared to
an untreated or sham operated control.
Total tissue protein carbonyl concentration was determined
using an ELISA method using the BioCell PC test kit (Biocell Corp,
Auckland, New Zealand) [38]. Tissue samples were ﬁrst homo-
genized [39] and the supernatant collected for protein quantiﬁ-
cation against a bovine serum albumin (BSA) standard and assayed
in triplicate (BCA Protein Assay kit, Pierce) prior to carbonyl
determination.
Statistics
Data are presented as means7SEM. Student's unpaired t-test
and analysis of variance (ANOVA) tests for difference between
groups were performed using GraphPad Prism software (v5.0a). A
p value of o0.05 was taken to be signiﬁcant.Results
MitoQ protects against IR induced kidney damage
To investigate whether MitoQ protected against kidney IR
damage in vivo we used an established mouse model of renal IR
injury [1,40]. To assess the impact of IR injury on kidney function
we measured plasma creatinine 24 h after IR injury and found that
30 min ischemia led to a mild increase in creatinine while 45 min
ischemia led to a far greater increase (Fig. 2A), indicative of sig-
niﬁcant kidney injury. We therefore used 45 min ischemia to
evaluate the efﬁcacy of MitoQ in reducing kidney injury. For this a
bolus of MitoQ was given 15 min before the onset of ischemia by a
single tail vein injection (Fig. 2B). MitoQ signiﬁcantly reduced
creatinine measured 24 h after reperfusion, while the control
compound dTPP did not (Fig. 2B). Therefore IR injury damages
kidney function and MitoQ signiﬁcantly decreases this
impairment.
MitoQ acts by decreasing mitochondrial oxidative damage
We next assessed whether the protection by MitoQ was due to
decreasing oxidative damage. Protein carbonyl levels, a widely-
used marker of oxidative damage, were increased in kidney
homogenates after 45 min ischemia and 24 h reperfusion, com-
pared to sham operated controls (Fig. 3A). Treatment with MitoQ
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Fig. 4. Oxidative damage to the kidney at the end of ischemia and after 60 min reperfusion. (A) At the end of 45 min ischemia (left graph) there was no difference in protein
carbonyl content between the sham group and the 45 min IR group or the MitoQ treated group (one-way ANOVA). After 60 min reperfusion (right graph) there was no
signiﬁcant difference between groups (one-way ANOVA). (b) mtDNA damage was measured using a quantitative PCR technique. As before, the sham operated control was
normalized to one and relative ampliﬁcation of mtDNA in the IR and MitoQ groups compared to this. There was no signiﬁcant difference in mtDNA damage levels between
the groups at the end of ischemia or after 60 min reperfusion (one-way ANOVA). n¼4/group. Data are means7SEM.
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level of controls (Fig. 3A). To focus on changes in mitochondria
damage we next assessed damage to mtDNA by a qPCR assay [35].
The basis of the assay is that ampliﬁcation of a long segment
(10 kbp) of mtDNA will be far more disrupted by random
damage than a short segment (200 bp). Consequently the rela-
tive ampliﬁcation of the long and short mtDNA segments indicates
the extent of mitochondrial oxidative damage [35]. A major
advantage of this assay is that there is no requirement to purify
mitochondria from the tissue as oxidative damage and MitoQ
treatment are likely to affect the yield and quality of the isolated
mitochondria, potentially skewing the interpretation of assays
based on isolated organelles. This assay showed extensive mito-
chondrial damage 24 h after IR injury, and indicated that MitoQ
decreased this damage signiﬁcantly (Fig. 3B). These ﬁndings are
consistent with a major increase in mitochondrial oxidative
damage within the kidney upon IR injury that underlies organ
dysfunction and which is prevented by MitoQ.
Timing of mitochondrial damage and protection by MitoQ
To investigate whether mitochondrial damage during kidney
injury occurred during ischemia, reperfusion or both, we assessed
howmuch damage occurred during ischemia alone (Fig. 4A and B).
Ischemia alone did not affect protein carbonyl levels or mtDNA
damage (Fig. 4A and B). Interestingly, there was little damage to
mtDNA when measured after 60 min reperfusion (Fig. 4B), com-
pared to 24 h reperfusion, implying that mtDNA damage occurred
over a long period following initial reperfusion. These data suggest
that mitochondrial damage continues during the reperfusion
process.Discussion
The role of mitochondria in the initiation and propagation of
renal IR injury has attracted increasing interest in recent years. It
has become clear that mitochondria are critical early responders to
the anoxia and reoxygenation that characterize IR injury, initiating
a broad range of responses which affect bioenergetic status, cal-
cium handling, induction of cell death pathways, autophagy and
activation of the inﬂammasome. Importantly from a therapeutic
perspective, many of these processes are triggered or augmented
by mitochondrial oxidative damage during reperfusion, when
mitochondria are both sources and targets of cellular Reactive
Oxygen Species (ROS). In this study, we have demonstrated that
administration of a mitochondria targeted antioxidant MitoQ,
reduces the severity of IR injury to the kidney by decreasing oxi-
dative damage.
The diagnosis of clinical AKI due to IR is typically based on an
elevation in plasma creatinine. There is a lag period between the
onset of kidney injury with the subsequent rise in creatinine
typically peaking 24 h after the ischemic insult [41]. Creatinine
levels at 24 h were therefore measured in our study as a marker of
functional kidney injury. We found that 45 min of bilateral renal
pedicle ischemia resulted in a signiﬁcant rise in serum creatinine
at 24 h, consistent with the functional injury observed in moder-
ately severe AKI. This allowed us to evaluate MitoQ in a clinically
relevant injury model. Using this model, we demonstrated that
administration of MitoQ prior to the onset of ischemia provided
functional protection to the kidney, presumably through its effect
in reducing oxidative damage to the renal tissue at reperfusion. As
MitoQ has already been safely used in Phase II clinical trials
[27,28], its role as a potential therapeutic agent in clinical IR injury
to the kidney warrants further exploration.
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